Kennard E Tan

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Many patients with metastatic transitional-cell carcinoma (TCC) are not appropriate candidates for standard cisplatin-based combination, because of inadequate renal function, poor performance status (PS), and other comorbid medical conditions. We have evaluated the efficacy and toxicity of a combination of carboplatin and vinblastine (CV) as a palliative(More)
  • 1